CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy · Terms of Service · Privacy FAQ

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
Biolevate›
Products & Services›
Biolevate AI-native Knowledge Platform›
Analysis
Biolevate AI-native Knowledge Platform

Biolevate AI-native Knowledge Platform

ProductOperating Status: Currently Offered

Biolevate’s AI-native knowledge platform standardizes scientific workflows for life sciences teams.

Loading
Overview
Analysis

Biolevate AI-native Knowledge Platform - Research Notes

  • Biolevate positions its platform around governed, auditable AI for regulated life sciences work: the company's Evidence Trail keeps claims, tables, figures, and recommendations connected to supporting sources, while versioned templates, controlled parameters, and defined review paths give subject-matter experts checkpoints to approve or reject AI-generated work.

    Its use-case pages cite workflow acceleration targets, such as faster systematic literature review cycles, signal triage, and regulatory change reviews, and the platform's zero-trust security design limits AI agents to granted, time-bound permissions, per the company site. Peer products in the cohort compete across narrower slices of these workflows: regulatory submission document management (Veeva Submissions), generative drafting inside Microsoft Word (Yseop Copilot), and submission-ready regulatory drafts (AMIA's Compliant Document Generator).

  • Biolevate was started in Paris by a founding team with Dataiku and pharmaceutical-industry backgrounds, and its first product prototype carried the name Elise, as reported at the company's €6 million seed round announcement in November 2024. The founding group reported at that time included chief executive Joël Belafa, chief operating officer Nathan Chen, chief technology officer Anas Laaroussi, and chief product officer Antoine De Torcy.

    The company states its platform was initially built to accelerate regulatory approval workflows and now spans research, clinical trials, health technology assessment, regulatory dossiers, and drug discovery and development. The offering still appears as the Biolevate ELISE platform in 2026 partner announcements, while the company's site presents its flagship as the AI-native Knowledge Platform.

  • The market context for AI knowledge platforms in life sciences is shaped by documentation pressure in regulated sectors. In its 22 September 2026 Series A announcement, Biolevate reported more than a dozen enterprise customers in production, a new Boston office, seven drafted patent applications with two filed in Europe, and a stated twentyfold increase in annual recurring revenue over the prior twelve months.

    The company's own materials describe the flagship as spanning the full life sciences value chain, from research and clinical trials to health technology assessment, regulatory dossiers, and drug discovery and development, and reporting around the round names partnerships with life sciences organizations and technology vendors. Competition for the platform comes from both incumbent regulatory suites and generative drafting tools, which continue to add governed authoring capabilities toward the same buyer base.

  • The Biolevate AI-native Knowledge Platform is Biolevate's platform for life sciences teams working in regulated environments. It connects scientific literature, regulatory frameworks, and expert procedures into a governed, source-linked knowledge base serving clinical, regulatory, market access, safety, and manufacturing workflows.

    The biolevate.com site presents the platform through roughly twenty workflow implementations, including clinical protocol and CSR co-authoring, regulatory dossier co-authoring, safety signal surveillance and triage, systematic literature review and evidence extraction, evidence-based competitive intelligence, batch records QC, and health technology assessment dossiers. Deployments run in a private cloud or on-premises, with ISO/IEC 27001 and 27701 certifications displayed on the company site.